Search Medical Condition
Please enter condition
Please choose location from dropdown

Schiltigheim, France Clinical Trials

A listing of Schiltigheim, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (449) clinical trials

Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

This is a multicenter, observational study of patients receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 200 patients across ~50 care centers in Europe and other regions over a period of ~ 2 years. The study population will include patients who ...

Phase N/A

1.53 miles

Learn More »

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.

Phase

1.53 miles

Learn More »

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

After surgery, most of patients with advanced ovarian/primitive peritoneal /fallopian carcinoma received as first line treatment, carboplatin plus paclitaxel plus or minus bevacizumab for 6 cycles followed by surveillance or bevacizumab maintenance therapy up to one year (GOG (Burger et al.), ICON7 (Perren et al.), French national guidelines Saint Paul ...

Phase

1.53 miles

Learn More »

An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus

This study will investigate BMS-986165 to assess its effects in patients with systemic lupus erythematosus (SLE).

Phase

1.53 miles

Learn More »

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

This database compiles data from Patient's Electronic medical records (EMR), inpatient Hospitalisation records and Pharmacy records. Patient Database: Patient-related data integrates data from non-structured sources (electronic medical records), such as patient medical records and reports of multidiscipline team meetings. It can provide information on patient demographics, primitive tumour, relapses, pathology ...

Phase N/A

1.53 miles

Learn More »

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

1.53 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Phase

1.53 miles

Learn More »

Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking. In this setting, a simple biological scoring system have recently been proposed, including LDH and CD138 binary status seric values, identifying one third of patients with worst prognostic. Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, ...

Phase

1.53 miles

Learn More »

Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients

The American Society of Clinical Oncology (ASCO) and the /College of American Pathologists (CAP) recommend that HER2 status (negative or positive) must be determined in all patients with invasive breast cancer. The knowledge of HER2 status will help the oncologist in prescribing or not a HER2-targeted therapy to patients. Presently, ...

Phase N/A

1.53 miles

Learn More »